undamentalytics Newsletter
Sign in

Newamsterdam Pharma Co N.V. (NAMS) stock

Add to watchlist

Add holding +

NASDAQ: NAMS Nasdaq Biotechnology Next results ~November 4, 2026

Newamsterdam Pharma Co N.V. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Newamsterdam Pharma Co N.V. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: limited reported history: available models are shown without a Buy/Hold/Sell rating. We'll show the comparison once resolved.

Newamsterdam Pharma Co N.V. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 6 selling1 purchase and 43 sales by directors and officers, last 12 monthsInsider trades
  • Funds116 adding, 69 cuttingOf 49 active managers that changed their stake, 32 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Newamsterdam Pharma Co N.V.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 53% and a beta of 1.4 against the S&P 500.
  • Heavily shorted. 13.8% of the shares available to trade are sold short (8.3 days of average volume to cover).
  • Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.

Latest results

Earnings per share
-$0.45 against an average estimate of -$0.43: missed by 5.7%
Share reaction
+0.4% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Next report
November 4, 2026; average EPS estimate -$0.44

Newamsterdam Pharma's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-2.5%
  • 1 week+0.2%
  • 1 month-15.7%
  • This year-44.2%
  • 1 year-48.5%
  • 5 years+100.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Insider trade
  2. Announcement
  3. Announcement
  4. Insider trade
  5. Leadership
  6. Results
  7. Announcement
  8. Leadership
  9. Insider trade

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Newamsterdam Pharma Co N.V. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, before the open. Analysts expect revenue of $6m and EPS of −$0.44 (range −$0.54 to −$0.29) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.66 −14% $25m +30%
Next −$1.55 +6% $120m +384%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +4.4% on 90 days ago. In the last 30 days, 2 analysts raised Newamsterdam Pharma Co N.V.'s forecast and 4 cut it.

Consensus EPS forecast Newamsterdam Pharma Co N.V., last 90 days
−$2.00 −$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.59 Current fiscal year, 60 days ago: −$1.66 Current fiscal year, 30 days ago: −$1.66 Current fiscal year, 7 days ago: −$1.65 Current fiscal year, Now: −$1.66 −$1.66 Next fiscal year, 90 days ago: −$1.32 Next fiscal year, 60 days ago: −$1.38 Next fiscal year, 30 days ago: −$1.53 Next fiscal year, 7 days ago: −$1.55 Next fiscal year, Now: −$1.55 −$1.55

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.59−$1.32
60 days ago −$1.66−$1.38
30 days ago −$1.66−$1.53
7 days ago −$1.65−$1.55
Now −$1.66−$1.55

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.43 −$0.45 −5.7%
Mar 2026 −$0.41 −$0.34 +16.5%
Dec 2025 −$0.37 −$0.53 −45.3%
Sept 2025 −$0.34 −$0.53 −54.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

16 analysts, Oct 2026
Buy1594%
Hold16%
Sell00%

Monthly trend

  1. Oct 202631216
  2. Sep 202631216
  3. Aug 202631216
  4. Jul 202631216

Counts of recommendations published by analysts covering Newamsterdam Pharma Co N.V., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
13.8%
of tradable shares
Days to cover
8.28
at average volume
Short interest, 1 month
−10%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
0.9%
of shares
Employees
100
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20222023202420252026 to date
Return
NAMS+12%+3%+130%+37%−44%
Industry peers (median)−57%−18%−29%−5%−26%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
NAMS75%42%67%42%27%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
NAMS−22%−66%−37%−43%−51%
S&P 500−25%−10%−8%−19%−9%

Worst fall since February 9, 2021: 66% from January 30, 2023 to October 25, 2023. Getting back needed a 196% gain, reached on January 19, 2024, 86 days after the low.

Price behaviour

52-week range
$19.53 – $41.45
From 52-week high
−52.8%
vs 50-day average
−13.8%
vs 200-day average
−34.2%
Volatility (1 year)
53%
Beta vs S&P 500
1.37

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±7.7%
After a week
7 up, 5 down
typical move ±11.3%
After a month
4 up, 8 down
typical move ±8.3%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 +0.4% −0.4% +1.0% −6.2%
May 7, 2026 +25.0% +0.5% +19.0% −0.1%
February 18, 2026 −1.7% +0.2% −0.7% −13.6%
January 9, 2026 −8.7% +0.8% −11.6% −2.5%
November 5, 2025 +1.4% −0.7% +4.9% −3.5%
August 6, 2025 +5.7% +0.7% +18.5% +24.3%
May 8, 2025 −2.9% +0.6% −1.2% +6.6%
February 26, 2025 +16.9% −1.5% +28.7% +25.3%
November 6, 2024 +18.2% +3.3% +28.5% −4.2%
August 7, 2024 +4.2% +1.6% +4.7% +1.0%
May 9, 2024 −1.7% +0.7% −8.0% −9.7%
February 28, 2024 −5.7% +0.2% −9.0% −2.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$4.1B
Institutions reporting
195
Shares held vs prior quarter
▼ 1.5%
Positions opened / closed
45 / 19

Top buyers and sellers, Q2 2026: 116 institutions bought and 69 sold ; the biggest buyer was Orbis Allan Gray Ltd (+1.7M shares) and the biggest seller Wellington Management Group LLP (−4.9M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Frazier Life Sciences Management, L.P. $613M 18.1M 14.8% ▲ 6.8%
Capital World Investors $414M 12.2M 10.0% ▲ 10.1%
FMR LLC $350M 10.3M 8.5% ▲ 18.0%
RA Capital Management, L.P. $324M 9.6M 7.8% 0.0%
Fcpm Iii Services B.V. $288M 8.5M 7.0% ▼ 7.7%
Deerfield Management Company, L.P. $145M 4.3M 3.5% 0.0%
Viking Global Investors LP $142M 4.2M 3.4% 0.0%
Bain Capital Life Sciences Investors, LLC $129M 3.8M 3.1% ▼ 47.9%
Maverick Capital Ltd $111M 3.3M 2.7% ▲ 49.5%
Duquesne Family Office LLC $104M 3.1M 2.5% 0.0%
Jupiter Topco LLC $86M 2.5M 2.1% —
Medicxi Ventures Management (Jersey) Ltd $74.9M 2.2M 1.8% ▼ 17.4%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Newamsterdam Pharma Co N.V.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $226,500 1 trade by 1 insider, last 12 months Insider sales History → $63.3M 43 trades by 6 insiders · 71% under pre-set plans
Net ▼ $63M net selling
Insider Date Trade Shares Price Value
Kastelein Johannes Jacob Pieter Chief Scientific Officer September 30, 2026 Sell pre-set plan 50,246 $25.03 $1.3M
Davidson Michael H. Chief Executive Officer September 14, 2026 Buy 10,000 $22.65 $226,500
Smither John W Director September 4, 2026 Sell 1,600 $25.32 $40,512
Kastelein Johannes Jacob Pieter Chief Scientific Officer August 24, 2026 Sell pre-set plan 125,000 $26.91 $3.4M
Kooij Louise Frederika Chief Accounting Officer July 20, 2026 Sell pre-set plan 70,200 $29.96 $2.1M
Kooij Louise Frederika Chief Accounting Officer July 20, 2026 Sell pre-set plan 31,885 $31.05 $990,029
Kooij Louise Frederika Chief Accounting Officer July 20, 2026 Sell pre-set plan 2,915 $31.71 $92,435
Kooij Louise Frederika Chief Accounting Officer June 22, 2026 Sell pre-set plan 39,700 $30.20 $1.2M
Kooij Louise Frederika Chief Accounting Officer June 22, 2026 Sell pre-set plan 300 $30.73 $9,219
Kooij Louise Frederika Chief Accounting Officer May 26, 2026 Sell pre-set plan 65,000 $35.69 $2.3M
Lange Louis G Director March 11, 2026 Sell 44,173 $30.41 $1.3M
Lange Louis G Director March 11, 2026 Sell 446 $31.23 $13,929

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 28, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 7, 2026
  • February 18, 2026
  • January 9, 2026
  • November 5, 2025
  • August 6, 2025

Recent SEC filings

Data status

When each part of this page on Newamsterdam Pharma Co N.V. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Newamsterdam Pharma Co N.V. in brief

What does Newamsterdam Pharma Co N.V. do?
Newamsterdam Pharma Co N.V. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Newamsterdam Pharma Co N.V.'s stock ticker?
Newamsterdam Pharma Co N.V. trades under the ticker NAMS on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Newamsterdam Pharma Co N.V.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Frazier Life Sciences Management, L.P., Capital World Investors and FMR LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Newamsterdam Pharma Co N.V. stock?
Over the last 12 months, Newamsterdam Pharma Co N.V.'s directors and officers reported 1 open-market purchases and 43 sales on Form 4. The insider trading page charts every trade.
When is Newamsterdam Pharma Co N.V.'s next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Newamsterdam Pharma Co N.V. announces its own schedule.